Welcome to the international HTA database

Showing [23368 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Edaravone in patients with amyotrophic lateral sclerosis]
2021	National Institute for Health and Care Excellence (NICE)	Ixekizumab for treating axial spondyloarthritis. NICE technology appraisal guidance 718
2021	NIHR Public Health Research (PHR) programme	A cluster randomised controlled trial of an intervention to improve the mental health support and training available to secondary school teachers the WISE (Wellbeing in Secondary Education) project
2021	European Network for Health Technology Assessment (EUnetHTA)	Bamlanivimab for the treatment of COVID-19
2021	NIHR Health Technology Assessment programme	Reducing bias in trials from reactions to measurement: the MERIT study including developmental work and expert workshop
2021	Health Sciences Institute in Aragon (IACS)	[Congenital ventricular septal defect (VSD) treatment with percutaneous and periventricular insertion devices]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Microvascular reperfusion after percutaneous coronary intervention for acute anterior myocardial infarction - Assessment according to §137h Social Code Book V]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Botulinum toxin in adult patients with overactive bladder]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Influence of COVID-19 vaccines on surgical practice
2021	National Institute for Health and Care Excellence (NICE)	Secukinumab for treating non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 719
2021	European Network for Health Technology Assessment (EUnetHTA)	Baricitinib for the treatment of COVID-19
2021	Health Information and Quality Authority (HIQA)	Analysis of factors associated with outbreaks of SARS-CoV-2 in nursing homes in Ireland
2021	Institute for Clinical and Economic Review (ICER)	Tezepelumab for severe asthma
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ipilimumab (NSCLC) - Addendum to Commission A20-116]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Vosoritide in achondroplasia]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Proposed delay for safe surgery after COVID-19
2021	National Institute for Health and Care Excellence (NICE)	Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma. NICE technology appraisal guidance 720
2021	European Network for Health Technology Assessment (EUnetHTA)	Molnupiravir for the treatment of COVID-19
2021	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Training programming for healthcare professionals: How to support patients with chronic diseases to self-manage their health]
2021	Canary Health Service	[Effectiveness of measures to close or restrict occupancy in cultural and entertainment places, in the context of the SARS-CoV-2 pandemic]
2021	Institute for Clinical and Economic Review (ICER)	Mavacamten for hypertrophic cardiomyopathy: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (NSCLC) - Addendum to Commission A20-118]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Auditory integration therapy for autism spectrum disorders]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Telehealth in surgery: an umbrella review
2021	National Institute for Health and Care Excellence (NICE)	Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 721
2021	European Network for Health Technology Assessment (EUnetHTA)	High-dose vitamin D for the treatment of COVID-19
2021	Ontario Health	Stance-control knee–ankle–foot orthoses for people with knee instability: a health technology assessment
2021	Institute for Clinical and Economic Review (ICER)	Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avelumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intense-pulse-light therapy treatment for dry eye syndrome]
2021	National Institute for Health and Care Excellence (NICE)	Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement. NICE technology appraisal guidance 722
2021	Center for Drug Evaluation (CDE)	[Health economic evaluation of three listed anti-cancer medications]
2021	European Network for Health Technology Assessment (EUnetHTA)	Mavrilimumab for the treatment of COVID-19
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Stool DNA testing for colorectal cancer (CRC) screening
2021	Institute for Clinical and Economic Review (ICER)	Observational real-world evidence update. Prophylaxis of hereditary angioedema with Takhzyro and C1 inhibitors: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Esketamine (depression) - Benefit assessment according to §35a Social Code Book V]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Tafamidis for transthyretin amyloid cardiomyopathy]
2021	National Institute for Health and Care Excellence (NICE)	Bimekizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 723
2021	Center for Drug Evaluation (CDE)	[Review of international guidelines and comparative effectiveness of high cost antidiabetes drugs]
2021	European Network for Health Technology Assessment (EUnetHTA)	Ivermectin for the treatment of COVID-19
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: hospital at home, an alternative to conventional hospitalization]
2021	Institute of Health Economics (IHE)	Optimizing vascular risk reduction initiatives in Alberta: a clinical review and economic analysis
2021	Institute for Clinical and Economic Review (ICER)	JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer. NICE technology appraisal guidance 724
2021	Center for Drug Evaluation (CDE)	[Descriptive study and comparative effectiveness of listed medications for osteoporosis on new osteoporotic fracture event in osteoporosis patients by using National Health Insurance claim database]
2021	European Network for Health Technology Assessment (EUnetHTA)	Aspirin for the treatment of COVID-19
2021	NIHR Health Technology Assessment programme	Non-invasive imaging software to assess the functional significance of coronary stenoses: a systematic review and economic evaluation
2021	Institute for Clinical and Economic Review (ICER)	Aducanumab for Alzheimer's disease: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[High-flow therapy for self-use in advanced COPD or chronic type 1 respiratory failure]
2021	National Institute for Health and Care Excellence (NICE)	Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 725
2021	Center for Drug Evaluation (CDE)	[A systematic review of the comparative efficacy and cost-effectiveness of current listed statins in Taiwan]
2021	NIHR Health Technology Assessment programme	The ACUTE (Ambulance CPAP: Use, Treatment effect and Economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure
2021	Swiss Federal Office of Public Health (FOPH)	Corneal collagen crosslinking for the treatment of progressive keratoconus
2021	Institute for Clinical and Economic Review (ICER)	Anti b-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Decision aid knee endoprosthesis]
2021	National Institute for Health and Care Excellence (NICE)	Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 726
2021	Swiss Federal Office of Public Health (FOPH)	Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis
2021	Institute for Clinical and Economic Review (ICER)	Belimumab and voclosporin for lupus nephritis: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Addendum to Commission A20-105]
2021	National Institute for Health and Care Excellence (NICE)	Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 727
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards: needs analysis grid for families followed by Integrated Perinatal and Early Childhood Services (SIPPE)]
2021	Institute for Clinical and Economic Review (ICER)	Treatments for anemia in chronic kidney disease: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tucatinib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Midostaurin for treating advanced systemic mastocytosis. NICE technology appraisal guidance 728
2021	Swiss Federal Office of Public Health (FOPH)	Medical cannabis for treating various symptoms in Switzerland
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Fall risk assessment in oncology patients
2021	Institute for Clinical and Economic Review (ICER)	Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: effectiveness and value
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Delaying surgery for patients recovering from COVID-19. A rapid review comissioned by RACS
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Phosphodiesterase type-5 inhibitors for the treatment of secondary Raynaud's phenomenon and digital ulcers
2021	National Institute for Health and Care Excellence (NICE)	Sapropterin for treating hyperphenylalaninaemia in phenylketonuria. NICE technology appraisal guidance 729
2021	Swiss Federal Office of Public Health (FOPH)	Palbociclib (Ibrance®), ribociclib (Kisqali®) and abemaciclib (Verzenios®) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor (HER2)-negative advanced breast cancer
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Effects of masks on the health of schoolchildren
2021	Canary Health Service	[Effectiveness and cost-effectiveness of universal eating disorders prevention in children, preadolescents and adolescents at school]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (oesophageal cancer) - Addendum to Commission A20-121]
2021	National Institute for Health and Care Excellence (NICE)	Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal). NICE technology appraisal guidance 730
2021	NIHR Health Technology Assessment programme	A non-inferiority randomised controlled trial comparing the clinical and cost-effectiveness of one session treatment (OST) with multi-session cognitive behavioural therapy (CBT) in children with specific phobias
2021	Ontario Health	Nonthermal endovenous treatments for varicose veins
2021	Swiss Federal Office of Public Health (FOPH)	Subacromial decompression as a primary/isolated intervention to treat subacromial pain
2021	NIHR Health Technology Assessment programme	Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal). NICE technology appraisal guidance 731
2021	Ontario Health	Prostatic artery embolization for benign prostatic hyperplasia
2021	Swiss Federal Office of Public Health (FOPH)	The treatment of hypercholesterolaemia and mixed/combined hyperlipidaemia with ezetimibe-containing medicines
2021	Belgian Health Care Knowledge Centre (KCE)	Long COVID: Pathophysiology – epidemiology and patient needs
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal). NICE technology appraisal guidance 732
2021	Ontario Health	Skin substitutes for adults with diabetic foot ulcers and venous leg ulcers
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: creation and characterization of a Québec lung cancer patient cohort using clinical administrative data]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Imlifidase (kidney transplantation) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. NICE technology appraisal guidance 733
2021	Ontario Health	Repetitive Transcranial Magnetic Stimulation for People With Treatment-Resistant Depression
2021	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Screening for common mental disorders during pregnancy and for traumatic experiences after delivery]
2021	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: consent process and disposition options for embryos preserved following in vitro fertilization]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fedratinib (myelofibrosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021	National Institute for Health and Care Excellence (NICE)	Secukinumab for treating moderate to severe plaque psoriasis in children and young people. NICE technology appraisal guidance 734
2021	Ontario Health	Pigmented lesion assay for suspected melanoma lesions
2021	Norwegian Institute of Public Health (NIPH)	[Liposuction (lipectomy) for the treatment of fat accumulation caused by chronic lymphoedema]
2021	Austrian Institute for Health Technology Assessment (AIHTA)	[Nivolumab in malignant melanoma: contrasting the evidence from pivotal trials with real world evidence (RWE)]